COHANCE.NS
COHANCE.NS
INE03QK01018
COHANCE LIFESCIENCES LTD
Loading chart...

Company Profile

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Related stocks

JUBLPHARMA.BO
JUBLPHARMA.BO • India
JUBILANT PHARMOVA LIMITED
931.2 INR
1.52B USD 1Y -14.2%
CAPLIPOINT.BO
CAPLIPOINT.BO • India
CAPLIN POINT LABORATORIES LTD.
2,459.55 INR
1.93B USD 1Y +27.1%
AKUMS.NS
AKUMS.NS • India
AKUMS DRUGS AND PHARMA L
751.85 INR
1.19B USD 1Y +78.6%
APLLTD.NS
APLLTD.NS • India
ALEMBIC PHARMA LTD
800.95 INR
1.63B USD 1Y -14%
SHILPAMED.BO
SHILPAMED.BO • India
SHILPA MEDICARE LTD.
1,020.35 INR
2.06B USD 1Y +187.4%
ASTRAZEN.BO
ASTRAZEN.BO • India
ASTRAZENECA PHARMA INDIA LTD.
5,831.85 INR
1.51B USD 1Y -38.5%
PPLPHARMA.NS
PPLPHARMA.NS • India
PIRAMAL PHARMA LIMITED
196.88 INR
2.7B USD 1Y -0.4%
ALIVUS.NS
ALIVUS.NS • India
ALIVUS LIFE SCIENCES LTD
1,326.3 INR
1.68B USD 1Y +45.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.0% p.a.
Max Drawdown (5Y)
-79.0%
Sharpe Ratio (5Y)
-0.19
Beta Factor
0.62
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 161.5 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (41.9%) is noticeably higher than the 5Y average (37.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -79.0% in the extended horizon.
ende